MX2024005745A - Metodo para tratar la esclerosis lateral amiotrofica y la pauta posologica para la misma. - Google Patents
Metodo para tratar la esclerosis lateral amiotrofica y la pauta posologica para la misma.Info
- Publication number
- MX2024005745A MX2024005745A MX2024005745A MX2024005745A MX2024005745A MX 2024005745 A MX2024005745 A MX 2024005745A MX 2024005745 A MX2024005745 A MX 2024005745A MX 2024005745 A MX2024005745 A MX 2024005745A MX 2024005745 A MX2024005745 A MX 2024005745A
- Authority
- MX
- Mexico
- Prior art keywords
- same
- lateral sclerosis
- amyotrophic lateral
- dosing regimen
- treating amyotrophic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163278523P | 2021-11-12 | 2021-11-12 | |
| PCT/US2022/049541 WO2023086468A1 (en) | 2021-11-12 | 2022-11-10 | Method of treating amyotrophic lateral sclerosis and dosing regimen for same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005745A true MX2024005745A (es) | 2024-05-28 |
Family
ID=86336738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005745A MX2024005745A (es) | 2021-11-12 | 2022-11-10 | Metodo para tratar la esclerosis lateral amiotrofica y la pauta posologica para la misma. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240415846A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4429667A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024543347A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118251226A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3236338A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005745A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023086468A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025207476A1 (en) * | 2024-03-25 | 2025-10-02 | Woolsey Pharmaceuticals, Inc. | Methods for treating als with a rho kinase inhibitor based on use of neurofilament light chain biomarker |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007050783A2 (en) * | 2005-10-26 | 2007-05-03 | Asahi Kasei Pharma Corporation | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
| EP2825175B1 (en) * | 2012-03-12 | 2017-07-26 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis |
| US20180055887A1 (en) * | 2016-08-23 | 2018-03-01 | Academia Sinica | Method for preparing induced mesenchymal stem cells and improving mesenchymal stem cell's characters and its applications |
| US11642352B2 (en) * | 2020-03-25 | 2023-05-09 | Woolsey Pharmaceuticals, Inc. | Methods of treating wandering in Lewy dody dementia |
-
2022
- 2022-11-10 CA CA3236338A patent/CA3236338A1/en active Pending
- 2022-11-10 CN CN202280074805.3A patent/CN118251226A/zh active Pending
- 2022-11-10 JP JP2024526916A patent/JP2024543347A/ja active Pending
- 2022-11-10 MX MX2024005745A patent/MX2024005745A/es unknown
- 2022-11-10 US US18/700,424 patent/US20240415846A1/en active Pending
- 2022-11-10 EP EP22893607.6A patent/EP4429667A4/en not_active Withdrawn
- 2022-11-10 WO PCT/US2022/049541 patent/WO2023086468A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024543347A (ja) | 2024-11-21 |
| WO2023086468A1 (en) | 2023-05-19 |
| US20240415846A1 (en) | 2024-12-19 |
| EP4429667A1 (en) | 2024-09-18 |
| EP4429667A4 (en) | 2025-09-17 |
| CN118251226A (zh) | 2024-06-25 |
| CA3236338A1 (en) | 2023-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000846A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| MX2023007853A (es) | Compuesto heterociclico puenteado que contiene nitrogeno, metodo de preparacion y uso medico del mismo. | |
| CO6311006A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas | |
| HRP20220277T1 (hr) | Liječenje fragilnog x sindroma i autizma kanabidiolom | |
| ECSP088762A (es) | Tratamiento del dolor | |
| JOP20230278A1 (ar) | تركيبة صيدلانية للوقاية من التليف أو علاجه | |
| BR112023021761A2 (pt) | Regime de dosagem de anti-ifnar1 para injeção subcutânea | |
| MX2025002439A (es) | Compuestos ciclicos de urea tiazolilo para el tratamiento del hsv | |
| MX2024004131A (es) | Ciertos 2,5-diazabiciclo[4.2.0]octanos como moduladores del receptor de glp-1. | |
| MX2023000868A (es) | Derivado de isoindolina que contiene azufre, metodo de preparacion y uso medico del mismo. | |
| EA201071043A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1 | |
| PH12015501184A1 (en) | Methods for whitening teeth | |
| CO6771410A2 (es) | Tratamiento terapeutico para el sindrome metabolico, diabetes tipo 2, obesidad o prediabetes | |
| MX2023006366A (es) | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. | |
| MX2024014578A (es) | Regimenes de dosis para tratamiento de infeccion de dengue | |
| MX2025005378A (es) | Metodos para el tratamiento de enfermedades cardiovasculares | |
| Halperson et al. | Dental pulp therapy for primary teeth in children undergoing cancer therapy | |
| EA202193178A1 (ru) | Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина | |
| AR125296A1 (es) | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 | |
| CL2025001708A1 (es) | Esquema de dosificación de una dispersión sólida de un inhibidor de her2 | |
| PE20240777A1 (es) | Proteinas actrii y usos de las mismas | |
| JOP20250164A1 (ar) | مركبات تعديل مستقبلات الدوبامين d3/d2 | |
| MX2025002288A (es) | Formulacion farmaceutica y regimen de dosificacion para el tratamiento de la esclerosis lateral amiotrofica | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
| MX2025004324A (es) | Metodo para tratar la esclerosis lateral amiotrofica mediante la administracion oral de fasudil |